Once heralded as the Holy Grail, the capability of obtaining a comprehensive list of genes, proteins or metabolites that are different between disease and normal is routine today. And yet, the holy grail of high-throughput has not delivered so far. Even though such high-throughput comparisons have become relatively easy to perform, understanding the phenomena that cause the disease is as challenging as ever, if not more so. Signaling and metabolic pathways are complex graphs describing genes signaling and biochemical reactions that take place in various subsystems of the organism. The current methods that aim to help us understand the underlying biological phenomena by using the measured differences to identify significantly impacted pathways are rather unsophisticated. Many if not all such methods of- ten treat the pathways as simple sets of genes, and either ignore or under-utilize the very essence of such pathways: the graphs that describe the complex ways in which genes interact with each other. We are proposing the development of a software product for the analysis of gene signaling and metabolic pathways in the context of high throughput data, such as DNA microarrays. The fundamentals of the approach have been tested through the implementation of tools available for free from the PI's academic web site. These tools have an existing user base of 11,266 registered users who already use and trust our software. This user-base constitutes a unique asset for Advaita. The product we envisage will have a number of unique capabilities including the ability to: i) take into consideration the interactions between specific genes;ii) calculate a unique """"""""impact factor"""""""" that characterizes how impacted a given subsystem of the organism is in the given condition;iii) find the mechanisms of action for diseases and drugs;iv) pinpoint potential points of optimal therapeutic intervention;and v) detect qualitative changes in a living organism by monitoring a large number of parameters (gene expression levels, metabolites, etc.). This product has the potential to: i) shorten the drug development cycle by providing fewer but better drug candidates, ii) help with the understanding of disease and drug mechanisms, iii) detect qualitative changes in biological organisms. The scientific validity of this analysis approach has been verified on real data in a number of applications (several published, others described here as preliminary results). The technical feasibility was demonstrated in over 36,000 benchmark trials. The commercial validity of this product has been verified by implementing a proto- type including the first 2 of the capabilities above. This prototype was already sold to 3 customers in spite of the fact that it only implements a small subset of the final set of capabilities and in spite of the fact that these customers already had access to the software products offered by our competition.

Public Health Relevance

The benefits of the proposed research are expected to impact a number of research areas spanning from cancer, to obesity, to aging as well as any other life science area in which high-throughput methods (e.g. DNA microarrays, protein microarrays, metabolomics, etc.) are used. The biological user community that can benefit from this research includes any life science researcher using such high-throughput methods in any biological domain and any organism, from yeast, to fruit fly, to mouse, to human.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Small Business Technology Transfer (STTR) Grants - Phase II (R42)
Project #
5R42GM087013-04
Application #
8479371
Study Section
Special Emphasis Panel (ZRG1-IMST-K (14))
Program Officer
Lyster, Peter
Project Start
2009-03-01
Project End
2014-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
4
Fiscal Year
2013
Total Cost
$727,410
Indirect Cost
Name
Advaita Corporation
Department
Type
DUNS #
198047529
City
Plymouth
State
MI
Country
United States
Zip Code
48170
Peyvandipour, Azam; Saberian, Nafiseh; Shafi, Adib et al. (2018) A novel computational approach for drug repurposing using systems biology. Bioinformatics 34:2817-2825
Nguyen, Tin; Mitrea, Cristina; Draghici, Sorin (2018) Network-Based Approaches for Pathway Level Analysis. Curr Protoc Bioinformatics 61:8.25.1-8.25.24
Shafi, Adib; Mitrea, Cristina; Nguyen, Tin et al. (2018) A survey of the approaches for identifying differential methylation using bisulfite sequencing data. Brief Bioinform 19:737-753
Talwar, Harvinder; Hanoudi, Samer Najeeb; Draghici, Sorin et al. (2018) Novel T7 Phage Display Library Detects Classifiers for Active Mycobacterium Tuberculosis Infection. Viruses 10:
Talwar, Harvinder; Hanoudi, Samer Najeeb; Geamanu, Andreea et al. (2017) Detection of Cystic Fibrosis Serological Biomarkers Using a T7 Phage Display Library. Sci Rep 7:17745
Nguyen, Tin; Tagett, Rebecca; Diaz, Diana et al. (2017) A novel approach for data integration and disease subtyping. Genome Res 27:2025-2039
Ansari, Sahar; Voichita, Calin; Donato, Michele et al. (2017) A novel pathway analysis approach based on the unexplained disregulation of genes. Proc IEEE Inst Electr Electron Eng 105:482-495
Nguyen, Tin; Mitrea, Cristina; Tagett, Rebecca et al. (2017) DANUBE: Data-driven meta-ANalysis using UnBiased Empirical distributions-applied to biological pathway analysis. Proc IEEE Inst Electr Electron Eng 105:496-515
Ahsan, Sidra; Dr?ghici, Sorin (2017) Identifying Significantly Impacted Pathways and Putative Mechanisms with iPathwayGuide. Curr Protoc Bioinformatics 57:7.15.1-7.15.30
Diaz, Diana; Donato, Michele; Nguyen, Tin et al. (2017) MICRORNA-AUGMENTED PATHWAYS (mirAP) AND THEIR APPLICATIONS TO PATHWAY ANALYSIS AND DISEASE SUBTYPING. Pac Symp Biocomput 22:390-401

Showing the most recent 10 out of 20 publications